Karolinska Institutet
Clinical Trials
1.1k
Trial Phases
6 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (858 trials with phase data)• Click on a phase to view related trials
Screening for Anal Cancer and Precancer in Women With HIV (SANCA)
- Conditions
- Anal Canal Cancer
- First Posted Date
- 2025-07-10
- Last Posted Date
- 2025-07-10
- Lead Sponsor
- Karolinska Institutet
- Target Recruit Count
- 1000
- Registration Number
- NCT07059442
- Locations
- 🇸🇪
Karolinska Institutet, Stockholm, Sweden
Objective Measurement of Pain Regulation in Individuals Who Have Received Internet-delivered Exposure-based Cognitive Behavior Therapy
- Conditions
- Fibromyalgia
- First Posted Date
- 2025-07-08
- Last Posted Date
- 2025-07-08
- Lead Sponsor
- Karolinska Institutet
- Target Recruit Count
- 50
- Registration Number
- NCT07054333
- Locations
- 🇸🇪
Karolinska Institutet, Solna, Sweden
🇸🇪Nobels väg 9, Neuro, Stockholm, Sweden
Intensive Trauma-Focused Treatment for Adolescents With Post-Traumatic Stress Disorder (PTSD): Feasibility and Preliminary Effects
- Conditions
- PTSD - Post Traumatic Stress Disorder
- First Posted Date
- 2025-07-04
- Last Posted Date
- 2025-07-04
- Lead Sponsor
- Karolinska Institutet
- Target Recruit Count
- 20
- Registration Number
- NCT07052474
- Locations
- 🇸🇪
Centre for Psychiatry Research, Stockholm, Sweden
Risk Factors and Outcomes in Patients Treated in Neurocritical Care
- Conditions
- Neuro-intensive Care Unit PatientsSubarachnoid Hemorrhage, AneurysmalIschemic StrokeIntracerebral HemorrhageStroke, AcuteMeningitisEpilepsyTraumatic Brain InjuryAcute Brain InjuriesAcute Neurological Injury
- First Posted Date
- 2025-07-04
- Last Posted Date
- 2025-07-10
- Lead Sponsor
- Karolinska Institutet
- Target Recruit Count
- 70000
- Registration Number
- NCT07052656
- Locations
- 🇸🇪
Karolinska University Hospital, Stockholm, Sweden
Swedish Cardiac And Renal Failure Study-1
- Conditions
- HFrEF - Heart Failure With Reduced Ejection FractionChronic Kidney Disease
- Interventions
- First Posted Date
- 2025-06-19
- Last Posted Date
- 2025-06-24
- Lead Sponsor
- Karolinska Institutet
- Target Recruit Count
- 40
- Registration Number
- NCT07029503
- Locations
- 🇸🇪
Department of Cardiology, Danderyd Hospital, Karolinska Institutet, Stockholm, Sweden
- Prev
- 1
- 2
- 3
- 4
- 5
- 207
- Next
News
Quince Therapeutics Strengthens Scientific Advisory Board with Leading Immunologist Ahead of Phase 3 Results
Quince Therapeutics appointed Dr. Hassan Abolhassani, a top-cited immunologist from Karolinska Institutet, to its Scientific Advisory Board as the ninth expert member.
ADHD Medication Benefits Diminish as Prescription Rates Rise, Swedish Study Reveals
A Swedish population study of 247,420 individuals found that ADHD medications consistently reduced risks of self-harm, unintentional injury, traffic crashes, and crime across all age groups and sexes.
Varenicline-Bupropion Combination Shows Promise for Alcohol Use Disorder Treatment
A 13-week randomized trial of 384 patients with moderate to severe alcohol use disorder found that combining varenicline and bupropion produced approximately twice the effect of currently available medications.
Alamar Biosciences Partners with SciLifeLab to Advance Precision Proteomics for Early Disease Detection
Alamar Biosciences has announced a strategic collaboration with Sweden's SciLifeLab to advance translational proteomics and accelerate biomarker discovery for early disease detection.
Belimumab Shows Superior Efficacy for Systemic Lupus Erythematosus in Meta-Analysis
A comprehensive meta-analysis of five randomized controlled trials confirms belimumab's superior efficacy over placebo in treating systemic lupus erythematosus (SLE) according to BICLA criteria.
Johnson & Johnson and Karolinska Institutet Celebrate Decade of Collaboration Advancing Medical Innovations
The ten-year partnership between Johnson & Johnson Innovative Medicine and Karolinska Institutet has yielded significant scientific advances across nine disease areas, with researchers working side by side since 2015.
Nanorobots for Drug Delivery Market Set to Reach $1.73 Billion by 2030, Transforming Precision Medicine
The global nanorobots for drug delivery market is projected to grow from $1.22 billion in 2025 to $1.73 billion by 2030, representing a CAGR of 7.05% as demand for targeted therapeutic solutions increases.
DiviTum® TKa Blood Test Shows Promise in Predicting Immunotherapy Response Across Multiple Cancers
New research from Karolinska Institutet demonstrates that Biovica's DiviTum® TKa blood test, when combined with inflammation protein biomarkers, significantly improves prediction of immunotherapy efficacy in melanoma patients.
Study Reveals Why Children's Cancer Immunotherapy Differs From Adults, Opening Path to Precision Medicine
Researchers at Karolinska Institutet discovered that children's tumors are less inflammatory and have fewer mutations than adults', explaining their reduced response to immunotherapy treatments.
Single-Dose HPV Vaccine Shows Promise in Long-Term Cervical Cancer Prevention Study
A landmark 17-year Swedish study of 2.2 million females reveals that one or two doses of HPV vaccine before age 17 provide similar protection against severe cervical lesions as the standard three-dose regimen.